⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRNX News
Crinetics Pharmaceuticals, Inc.
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
prnewswire.com
GTBP
ADCT
STRO
CRNX
TCRX
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
CRNX
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector
businesswire.com
CRNX
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CRNX
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
globenewswire.com
CRNX
Veeva AI Agents Now Available to Increase Productivity and Customer Centricity USA - English USA - English
prnewswire.com
VEEV
BMY
MRNA
NVO
OTK
CRNX
Veeva AI Agents Now Available to Increase Productivity and Customer Centricity USA - English USA - English
prnewswire.com
VEEV
BMY
MRNA
NVO
OTK
CRNX
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
prnewswire.com
CRNX
NVS
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
globenewswire.com
CRNX